Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol 2023;34:543-552. [PMID: 36921693 DOI: 10.1016/j.annonc.2023.02.016] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 02/24/2023] [Accepted: 02/24/2023] [Indexed: 03/14/2023] Open

For:	Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol 2023;34:543-552. [PMID: 36921693 DOI: 10.1016/j.annonc.2023.02.016] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 02/24/2023] [Accepted: 02/24/2023] [Indexed: 03/14/2023] Open

Number

Cited by Other Article(s)

Marsicano RM, Boscolo Bielo L, Rocco EG, Lombardi M, Bertani E, Bassi FM, Curigliano G, Ciardiello D, Fazio N, Zampino MG. Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case. Clin Colorectal Cancer 2025:S1533-0028(25)00030-1. [PMID: 40240266 DOI: 10.1016/j.clcc.2025.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Revised: 03/18/2025] [Accepted: 03/20/2025] [Indexed: 04/18/2025]

Catani G, Kim S, Waisberg F, Enrico D, Luca R, Esteso F, Bruno L, Rodríguez A, Bortz M, Freile B, Chacón M, Oviedo Albor AI, Méndez G, Slutsky E, Baiud MC, Llanos R, Solonyezny A, Basbus L, Arroyo G, Grasselli J, Pasquinelli R, Bella Quero L, Faura MV, Adur AC, Dioca M, Tamburelli M, Castillo J, O’Connor JM. Patients with Colorectal Cancer and BRAF^V600E-Mutation in Argentina: A Real-World Study-The EMOGI-CRC01 Study. Cancers (Basel) 2025;17:1007. [PMID: 40149341 PMCID: PMC11941482 DOI: 10.3390/cancers17061007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2025] [Revised: 02/25/2025] [Accepted: 02/27/2025] [Indexed: 03/29/2025] Open

Affiliation(s)

Greta Catani Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina; (F.W.); (D.E.); (M.B.); (M.C.) Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.)
Stefano Kim Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Sanatorio Allende, Córdoba X5000BFB, Argentina; (M.C.B.); (R.L.); (A.S.) European Oncology Institute Strasbourg, Department Medical Oncology, CEDEX 67200 Strasbourg, France
Federico Waisberg Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina; (F.W.); (D.E.); (M.B.); (M.C.)
Diego Enrico Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina; (F.W.); (D.E.); (M.B.); (M.C.)
Romina Luca Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;
Federico Esteso Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;
Luisina Bruno Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;
Andrés Rodríguez Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;
Marcos Bortz Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina; (F.W.); (D.E.); (M.B.); (M.C.) Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.)
Berenice Freile Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;
Matías Chacón Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina; (F.W.); (D.E.); (M.B.); (M.C.)
Ana Isabel Oviedo Albor Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Dr. C.B. Udaondo Hospital, Buenos Aires 1264, Argentina
Guillermo Méndez Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Dr. C.B. Udaondo Hospital, Buenos Aires 1264, Argentina
Ezequiel Slutsky Department of Oncology, Favaloro Foundation, Buenos Aires 1093, Argentina;
María Cristina Baiud Department of Oncology, Sanatorio Allende, Córdoba X5000BFB, Argentina; (M.C.B.); (R.L.); (A.S.)
Romina Llanos Department of Oncology, Sanatorio Allende, Córdoba X5000BFB, Argentina; (M.C.B.); (R.L.); (A.S.)
Ayelen Solonyezny Department of Oncology, Sanatorio Allende, Córdoba X5000BFB, Argentina; (M.C.B.); (R.L.); (A.S.)
Luis Basbus Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Hospital Italiano Buenos Aires, Buenos Aires 1199, Argentina
Gerardo Arroyo Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Centro de Diagnóstico, Investigación y Tratamiento, Salta 4400, Argentina
Julieta Grasselli Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, CEMIC, Buenos Aires 1431, Argentina;
Rosario Pasquinelli Department of Oncology, CEMIC, Buenos Aires 1431, Argentina;
Luciana Bella Quero Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Hospital Británico, Buenos Aires 1280, Argentina;
María Victoria Faura Department of Oncology, Hospital Británico, Buenos Aires 1280, Argentina;
Ana Cecilia Adur Department of Gastrointestinal Tumors, Instituto de Oncología Ángel H. Roffo, Buenos Aires 1417, Argentina;
Mariano Dioca Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Instituto de Oncología Ángel H. Roffo, Buenos Aires 1417, Argentina;
Mercedes Tamburelli Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Hospital Alemán, Buenos Aires 1425, Argentina
Javier Castillo Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Oncology, Hospital Alemán, Buenos Aires 1425, Argentina
Juan Manuel O’Connor Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Federico Lacroze 2252, Argentina; (S.K.); (F.E.); (L.B.); (A.R.); (B.F.); (A.I.O.A.); (G.M.); (L.B.); (G.A.); (J.G.); (L.B.Q.); (M.D.); (M.T.); (J.C.); (J.M.O.) Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires 1426, Argentina;

Collapse

Gutiérrez Pérez C, Lastra Aras E, Saiz López P, García Toro E, Blanco Abad C, Rodríguez Ledesma I, Pumares González M, Vela Domínguez M, Espinosa Cabria N, Crespo Herrero G. Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies. Clin Transl Oncol 2025;27:1211-1220. [PMID: 39147936 DOI: 10.1007/s12094-024-03651-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 07/29/2024] [Indexed: 08/17/2024]

Napolitano S, Ciardiello D, Cioli E, Martinelli E, Troiani T, Giulia Zampino M, Fazio N, De Vita F, Ciardiello F, Martini G. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat Rev 2025;134:102905. [PMID: 40009904 DOI: 10.1016/j.ctrv.2025.102905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2025] [Revised: 02/19/2025] [Accepted: 02/19/2025] [Indexed: 02/28/2025]

Ono Y, Numata K, Iguchi K, Uchiyama M, Asari M, Rino Y, Saito A, Shiozawa M. Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the BRAF V600E Mutation. CANCER DIAGNOSIS & PROGNOSIS 2025;5:216-222. [PMID: 40034953 PMCID: PMC11871857 DOI: 10.21873/cdp.10432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/02/2024] [Revised: 12/21/2024] [Accepted: 01/21/2025] [Indexed: 03/05/2025]

Piercey O, Chantrill L, Hsu H, Ma B, Price T, Tan IB, Teng H, Tie J, Desai J. Expert consensus on the optimal management of BRAF^V600E-mutant metastatic colorectal cancer in the Asia-Pacific region. Asia Pac J Clin Oncol 2025;21:31-45. [PMID: 39456063 PMCID: PMC11733838 DOI: 10.1111/ajco.14132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2024] [Revised: 09/14/2024] [Accepted: 10/09/2024] [Indexed: 10/28/2024]

Fox DA, Bhamidipati D, Kopetz S, Hong DS. Durable Remission After Targeted Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Case Report. JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY 2025;8:11-14. [PMID: 39811421 PMCID: PMC11728385 DOI: 10.36401/jipo-24-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 08/20/2024] [Accepted: 08/22/2024] [Indexed: 01/16/2025]

Colombo A, Concetta PM, Gebbia V, Sambataro D, Scandurra G, Valerio MR. A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation. In Vivo 2025;39:25-36. [PMID: 39740863 PMCID: PMC11705148 DOI: 10.21873/invivo.13802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2024] [Revised: 09/26/2024] [Accepted: 09/30/2024] [Indexed: 01/02/2025]

Ciracì P, Studiale V, Taravella A, Antoniotti C, Cremolini C. Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. Nat Rev Clin Oncol 2025;22:28-45. [PMID: 39558030 DOI: 10.1038/s41571-024-00965-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/25/2024] [Indexed: 11/20/2024]

Ros J, Ucha JM, Garcia-Galea E, Gomez P, Martini G, Balconi F, Comas R, Alonso V, Rodriguez M, Baraibar I, Salva F, Saoudi N, Alcaraz A, Garcia A, Tabernero J, Elez E. Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. Cancers (Basel) 2024;16:4140. [PMID: 39766040 PMCID: PMC11674344 DOI: 10.3390/cancers16244140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2024] [Revised: 12/05/2024] [Accepted: 12/10/2024] [Indexed: 01/11/2025] Open

Roazzi L, Patelli G, Bencardino KB, Amatu A, Bonazzina E, Tosi F, Amoruso B, Bombelli A, Mariano S, Stabile S, Porta C, Siena S, Sartore-Bianchi A. Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer. Clin Colorectal Cancer 2024;23:295-308. [PMID: 38519391 DOI: 10.1016/j.clcc.2024.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/04/2024] [Accepted: 02/11/2024] [Indexed: 03/24/2024]

Affiliation(s)

Laura Roazzi Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Giorgio Patelli Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy
Katia Bruna Bencardino Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Alessio Amatu Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Erica Bonazzina Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Federica Tosi Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Brunella Amoruso Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
Anna Bombelli Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Sara Mariano Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Stefano Stabile Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Camillo Porta Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
Salvatore Siena Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Andrea Sartore-Bianchi Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Division of Clinical Research and Innovation, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Collapse

De Giglio A, Zacchini F, Venturi G, Di Federico A, Parisi C, Dall’Olio FG, Ricciotti I, Favorito V, Gagliano A, De Biase D, Maloberti T, Altimari A, Gruppioni E, Tallini G, Melotti B, Sperandi F, Gelsomino F, Montanaro L, Ardizzoni A. Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report. THE JOURNAL OF LIQUID BIOPSY 2024;6:100161. [PMID: 40027319 PMCID: PMC11863973 DOI: 10.1016/j.jlb.2024.100161] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/26/2024] [Accepted: 06/20/2024] [Indexed: 03/05/2025]

Abstract

Background

The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-positive NSCLC presents a spectrum of treatment options, including ICIs, targeted therapy and combination strategies currently under investigation.

Methods

We conducted a prospective project to detect circulating tumor DNA (ctDNA) in patients with KRAS G12C, advanced NSCLC. We included patients undergoing upfront ICIs or subsequent line sotorasib. We planned three-time points: baseline (T0), after 3 months of treatment (T1) and at disease progression (T2).

Results

24 consecutive patients have been included. The most frequent baseline characteristics were: nonsquamous histology (95.8%), male gender (62.5%), ECOG PS 0-1 (79.2%), <3 metastatic sites (13/24, 54.2%). 18 patients (75%) received ICI-based strategies and 6 patients (25%) sotorasib. Patients with liver metastases (p = 0.01) and those with >3 metastatic sites (p = 0.002) exhibited significantly elevated ctDNA. Median overall survival (OS) was 7.5 months, progression-free survival (PFS) was 4.0 months and the objective response rate (ORR) was 33.3%. Higher AF correlated with an increased risk of death (HR 1.04, p = 0.03), though not progression. The mOS was 7.5 months (95% CI, 1.91-NR) in high-AF group and 11.3 months (95% CI, 6.6-NR) in low-AF group (p = 0.38). Notably, a reduction in plasma DNA levels was significantly associated with objective response (p = 0.01). Two patients received a T2 dosage showing increased ctDNA levels after a previous reduction associated with response.

Conclusion

Early monitoring with ctDNA may offer potential benefits in the evolving scenario of KRAS G12C NSCLC treatment.

Collapse

Affiliation(s)

Andrea De Giglio Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Federico Zacchini Departmental Program in Laboratory Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Giulia Venturi Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Alessandro Di Federico Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Claudia Parisi Department of Medical Oncology, Gustave Roussy, Villejuif, France Faculty of Medicine, Paris-Saclay University, Paris, France
Filippo Gustavo Dall’Olio Department of Medical Oncology, Gustave Roussy, Villejuif, France
Ilaria Ricciotti Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Valentina Favorito Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Ambrogio Gagliano Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Dario De Biase Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
Thais Maloberti Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Annalisa Altimari Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Elisa Gruppioni Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Giovanni Tallini Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Barbara Melotti Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Francesca Sperandi Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Francesco Gelsomino Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Lorenzo Montanaro Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Departmental Program in Laboratory Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Andrea Ardizzoni Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Collapse

Simhadri S, Carrick JN, Murphy S, Kothari OA, Al-Hraishami H, Kulkarni A, Jalloul N, Stefanik K, Bandari M, Chettur K, Yao M, Ginjala V, Groisberg R, Hochster H, Mehnert J, Riedlinger G, Khiabanian H, Verzi MP, Tong K, Ganesan S. Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer. JCO Precis Oncol 2024;8:e2300260. [PMID: 39626159 PMCID: PMC11627326 DOI: 10.1200/po.23.00260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 06/28/2024] [Accepted: 09/27/2024] [Indexed: 12/11/2024] Open

Affiliation(s)

Srilatha Simhadri Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Jillian N. Carrick Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway Township, NJ Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ
Susan Murphy Department of Medicine, Pediatric Hematology/Oncology Program, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Om A. Kothari Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway Township, NJ
Husam Al-Hraishami Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Atul Kulkarni Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Nahed Jalloul Department of Pathology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Katarina Stefanik Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway Township, NJ Department of Biology, The College of New Jersey, Ewing, NJ
Manisha Bandari Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ
Kavya Chettur Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ Tenafly High School, Tenafly, NJ
Ming Yao Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Vasudeva Ginjala Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Roman Groisberg Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Howard Hochster Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Janice Mehnert Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Gregory Riedlinger Department of Pathology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Hossein Khiabanian Department of Pathology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ
Michael P. Verzi Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway Township, NJ
Kevin Tong Department of Genetics, Human Genetics Institute of New Jersey, Rutgers University, Piscataway Township, NJ Department of Biology, The College of New Jersey, Ewing, NJ Department of Medical Sciences, Hackensack Meridian Health School of Medicine, Nutley, NJ
Shridar Ganesan Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ

Collapse

Liu M, Liu Q, Hu K, Dong Y, Sun X, Zou Z, Ji D, Liu T, Yu Y. Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment. Crit Rev Oncol Hematol 2024;204:104497. [PMID: 39245296 DOI: 10.1016/j.critrevonc.2024.104497] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Revised: 08/29/2024] [Accepted: 08/31/2024] [Indexed: 09/10/2024] Open

Cardone C, Facchini S, de Stefano A, Rachiglio AM, Avallone A. Transient 'NeoBRAF wild type' state in a patient with BRAF^V600E mutant metastatic colorectal cancer. Cytopathology 2024;35:671-673. [PMID: 39086078 DOI: 10.1111/cyt.13429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Revised: 07/08/2024] [Accepted: 07/15/2024] [Indexed: 08/02/2024]

Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer. EBioMedicine 2024;108:105352. [PMID: 39303668 PMCID: PMC11437914 DOI: 10.1016/j.ebiom.2024.105352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 09/02/2024] [Accepted: 09/04/2024] [Indexed: 09/22/2024] Open

Abstract

BACKGROUND

We studied the poorly-known dynamics of circulating DNA (cir-nDNA), as monitored prospectively over an extended post-surgery period, in patients with cancer.

METHODS

On patients with stage III colon cancer (N = 120), using personalised molecular tags we carried out the prospective, multicenter, blinded cohort study of the post-surgery serial analysis of cir-nDNA concentration. 74 patients were included and 357 plasma samples tested.

FINDINGS

During post-operative follow-up, the patients' median cir-nDNA concentration was greater (P < 0.0001 in the [43-364 days range]) than both the median value in healthy individuals and the pre-surgery value. These cir-nDNA levels were highly associated with NETs markers (P-value associating MPO and cir-nDNA, and NE and cir-nDNA are 6.6 x 10-17, and 1.9 x 10-7), in accordance with previous reports which indicate that cir-nDNA are NETs by-products. Unexpectedly, in 34 out of 50 patients we found that NETs continued to be formed for an extended duration post-surgery, even in patients without disease progression. Given that this phenomenon was observed in patients without adjuvant CT, and in patients >18 months post-surgery, the data suggest that the persistence of NETs formation is not due to the adjuvant CT.

INTERPRETATION

(1), Given the inter-patient heterogeneity, the post-surgery cir-nDNA level cannot be considered a reliable value, and caution must be exercised when determining mutation allele frequency or the mutation status; and (2), specific studies must be undertaken to investigate the possible clinical impact of the persistent, low-grade inflammation resulting from elevated NETs levels, such as observed in these post-surgery patients, given that such levels are known to potentially induce adverse cardiovascular or thrombotic events.

FUNDING

This work was supported by the H2020 European ERA-NET grant on Translational Cancer Research (TRANSCAN-2).

Collapse

Affiliation(s)

Alexia Mirandola IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Andrei Kudriavtsev IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Catalina Isabel Cofre Muñoz Medical Oncology Department, Institut Català d'Oncologia (ICO) - IDIBELL, Barcelona, Spain
Raquel Comas Navarro VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Marco Macagno Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Saidi Daoud IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Cynthia Sanchez IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Brice Pastor IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Ekaterina Pisareva IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Mireia Sanchis Marin VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Javier Gonzalo Ruiz VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Alejandro Piris VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Ariadna Garcia Rodriguez VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Nadia Saoudi Gonzalez VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Ana Vivancos VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Virginia Quarà Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Alfredo Mellano Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Felice Borghi Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Giorgio Corti Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Caterina Marchiò Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy; Department of Medical Sciences, University of Torino, Turin, Italy
Anna Sapino Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy; Department of Medical Sciences, University of Torino, Turin, Italy
Alice Bartolini Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Giovanni Crisafulli IFOM, The AIRC Institute of Molecular Oncology, Milan, Italy; Department of Oncology, University of Torino, Turin, Italy
Alberto Bardelli IFOM, The AIRC Institute of Molecular Oncology, Milan, Italy; Department of Oncology, University of Torino, Turin, Italy
Massimo Di Maio Department of Oncology, University of Torino, Turin, Italy
Gerald Lossaint ICM, Institut Régional du Cancer de Montpellier, Montpellier, F-34298, France
Florence Frayssinoux IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France
Evelyne Crapez IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France; ICM, Institut Régional du Cancer de Montpellier, Montpellier, F-34298, France
Marc Ychou IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France; ICM, Institut Régional du Cancer de Montpellier, Montpellier, F-34298, France
Ramon Salazar Soler Medical Oncology Department, Institut Català d'Oncologia (ICO) - IDIBELL, Barcelona, Spain
Elisabetta Fenocchio Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Paula X Fernandez Calotti Medical Oncology Department, Institut Català d'Oncologia (ICO) - IDIBELL, Barcelona, Spain
Thibault Mazard IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France; ICM, Institut Régional du Cancer de Montpellier, Montpellier, F-34298, France
Cristina Santos Vivas Medical Oncology Department, Institut Català d'Oncologia (ICO) - IDIBELL, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain
Elena Elez VHIO Vall d'Hebron Institute of Oncology, Medical Oncology Department, Barcelona, Spain
Federica Di Nicolantonio Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy; Department of Oncology, University of Torino, Turin, Italy
Alain R Thierry IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, F-34298, France; ICM, Institut Régional du Cancer de Montpellier, Montpellier, F-34298, France.

Collapse

Kourie HR, Zouein J, Zalaquett Z, Chebly A, Nasr L, Karak FE, Sadek M, Safar O, Fouani M, Bitar N, Kachmar K, Nasr F, Farhat F, Makarem J, Kattan J, Taieb J. Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer. Clin Res Hepatol Gastroenterol 2024;48:102417. [PMID: 39009221 DOI: 10.1016/j.clinre.2024.102417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 07/08/2024] [Accepted: 07/09/2024] [Indexed: 07/17/2024]

Abstract

BACKGROUND

The absence of KRAS and NRAS gene mutations (RAS wild type) in metastatic colorectal cancer (mCRC), is associated with a good response to targeted therapy with anti-EGFR receptor antibodies. The current gold standard for RAS mutational status identification is genetic testing on tissue biopsy samples.

OBJECTIVE

This study aimed to assess the relevance of liquid biopsy as a less invasive alternative to tissue biopsy for detecting KRAS/NRAS and BRAF mutations in patients with metastatic colorectal cancer (mCRC). The study also aimed to determine the concordance between liquid biopsy and tissue biopsy.

METHODS

This is a phase IV, observational, uncontrolled, non-comparative, non-randomized, open label study. RAS/BRAF status will be tested at baseline using tissue and liquid biopsy using the Idylla/Biocartis PCR-based device. The primary endpoint is the comparison of the RAS status based on liquid biopsy with the RAS status based on tissue biopsy.

RESULTS

100 patients with mCRC were included in the study. 75 % of patients showed concordant results between liquid biopsy and tissue biopsy, while 25 % had discordant results. Liquid biopsy demonstrated a sensitivity of 62 % and a specificity of 93 %. The accuracy of liquid biopsy was 75 %, with a moderate agreement between the two tests. The most frequent mutations in concordant cases were in KRAS (41 %), followed by NRAS (4 %) and BRAF (3 %). Mutations were not detected in 42 % of tissue biopsy samples and 60 % of liquid biopsy samples. The presence of hepatic metastases did not significantly affect the concordance between the biopsy methods.

CONCLUSION

Liquid biopsy using the Idylla™ system showed a relatively low sensitivity but high specificity for detecting KRAS/NRAS and BRAF mutations in mCRC patients. Despite some discordant cases, liquid biopsy remains a promising alternative to tissue biopsy due to its non-invasiveness, ability to provide multiple samples, and better representation of tumor heterogeneity.

Collapse

Affiliation(s)

Hampig Raphael Kourie Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon.
Joseph Zouein Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon; Department of Medicine, Duke University Medical Center, Durham, NC, USA
Ziad Zalaquett Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon
Alain Chebly Jacques Loiselet Center for Medical Genetics and Genomics (CGGM), Faculty of Medicine, Saint Joseph University, Beirut, Lebanon; Higher Institute of Public Health, Saint Joseph University, Beirut, Lebanon
Lewis Nasr Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon
Fadi El Karak Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon
Maroun Sadek Hematology-Oncology Department, Lebanese Hospital Geitaoui, Beirut, Lebanon
Ousama Safar Dar Al Amal University Hospital, Bekaa, Lebanon
Mouin Fouani Saint George Hospital, Hadath, Lebanon
Nizar Bitar Sahel General Hospital, Beirut, Lebanon
Kamal Kachmar Tebnin Governmental Hospital, Bekaa, Lebanon
Fady Nasr Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon
Fadi Farhat Mount Lebanon Hospital, Baabda, Lebanon
Jawad Makarem Al Jabal Hospital, Chouf, Lebanon
Joseph Kattan Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University, Boulevard Alfred Naccache, Beirut, Lebanon
Julien Taieb Hôpital Européen Georges Pompidou, Paris, France

Collapse

Hashem O, Shahin AI, Al Hindawi MA, Fageeri MF, Al-Sbbagh SA, Tarazi H, El-Gamal MI. An overview of RAF kinases and their inhibitors (2019-2023). Eur J Med Chem 2024;275:116631. [PMID: 38954961 DOI: 10.1016/j.ejmech.2024.116631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 06/23/2024] [Accepted: 06/24/2024] [Indexed: 07/04/2024]

Piercey O, Tie J, Hollande F, Wong HL, Mariadason J, Desai J. BRAF^V600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities. Clin Colorectal Cancer 2024;23:215-229. [PMID: 38816264 DOI: 10.1016/j.clcc.2024.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Accepted: 04/24/2024] [Indexed: 06/01/2024]

Gallois C, Bergen ES, Auclin É, Pernot S, Higué J, Trouilloud I, Touchefeu Y, Turpin A, Mazard T, Sartore-Bianchi A, Prenen H, Alberti A, Pilla L, Cuissy S, Wookey V, Perret A, Melchior C, Artru P, Dubreuil O, Drouillard A, Doat S, Lavolé J, Basile D, Perkins G, Jary M, Stintzing S, Ros J, Tougeron D, Taieb J. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study. ESMO Open 2024;9:103696. [PMID: 39255538 PMCID: PMC11415680 DOI: 10.1016/j.esmoop.2024.103696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Revised: 07/30/2024] [Accepted: 08/05/2024] [Indexed: 09/12/2024] Open

Abstract

BACKGROUND

The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after a prior systemic therapy. This study aims to describe the efficacy and safety of encorafenib/cetuximab +/- binimetinib in patients with BRAF V600E-mutated mCRC in a real-world setting.

PATIENTS AND METHODS

This retrospective study included patients with BRAF V600E-mutated mCRC who received this combination from January 2020 to June 2022 in 30 centers.

RESULTS

A total of 201 patients were included, with 55% of women, a median age of 62 years, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) >1 in 20% of cases. The main tumor characteristics were 60% of right-sided primary tumor, 11% of microsatellite instability/mismatch repair deficient phenotype, and liver and peritoneum being the two main metastatic sites (57% and 51%). Encorafenib/cetuximab +/- binimetinib was prescribed in the first, second, third, and beyond third line in 4%, 56%, 29%, and 11%, respectively, of cases, with the encorafenib/cetuximab/binimetinib combination for 21 patients (10%). With encorafenib/cetuximab treatment, 21% of patients experienced grade ≥3 adverse events (AEs), with each type of grade ≥3 AE observed in <5% of patients. The objective response rate was 32.2% and the disease control rate (DCR) was 71.2%. The median progression-free survival (PFS) was 4.5 months [95% confidence interval (CI) 3.9-5.4 months] and the median overall survival (OS) was 9.2 months (95% CI 7.8-10.8 months). In multivariable analysis, factors associated with a shorter PFS were synchronous metastases [hazard ratio (HR) 1.66, P = 0.04] and ECOG-PS >1 (HR 1.88, P = 0.007), and those associated with a shorter OS were the same factors (HR 1.71, P = 0.03 and HR 2.36, P < 0.001, respectively) in addition to treatment beyond the second line (HR 1.74, P = 0.003) and high carcinoembryonic antigen level (HR 1.72, P = 0.003).

CONCLUSION

This real-world study showed that in patients with BRAF V600E-mutated mCRC treated with encorafenib/cetuximab +/- binimetinib, efficacy and safety data confirm those reported in the BEACON registration trial. The main poor prognostic factors for this treatment are synchronous metastases and ECOG-PS >1.

Collapse

Affiliation(s)

C Gallois Department of Gastroenterology and Digestive Oncology, Paris-Cité University, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France
E S Bergen Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
É Auclin Medical and Thoracic Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
S Pernot Department of Medical Oncology, Institut Bergonié, Bordeaux, France
J Higué Centre Hospitalier Universitaire de Toulouse, Toulouse, France
I Trouilloud Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP, Paris, France
Y Touchefeu Digestive Oncology, Institut Des Maladies De l'Appareil Digestif, Centre Hospitalier Universitaire De Nantes, Nantes, France
A Turpin Department of Medical Oncology, University Lille, Lille, France; UMR9020 CNRS, UMR-S1277 Inserm, Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, CHU Lille, Lille, France
T Mazard Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier, Montpellier, France
A Sartore-Bianchi Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
H Prenen University Hospital Antwerp, Edegem, Belgium
A Alberti Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy
L Pilla Department of Gastroenterology and Digestive Oncology, Paris-Cité University, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France
S Cuissy Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France
V Wookey Department of Oncology, Mayo Clinic, Rochester, USA
A Perret Department of Medical Oncology, Gustave Roussy Cancer Centre, Villejuif, France
C Melchior Department of Medical Oncology, Centre Léon Bérard, Lyon, France
P Artru Hepatogastroenterology Department, Hôpital Jean-Mermoz, Lyon, France
O Dubreuil Department of Digestive Oncology, Groupe hospitalier Diaconesses Croix Saint Simon, Paris, France
A Drouillard Department of Hepato-Gastroenterology, Dijon Hospital, Dijon, France
S Doat Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France
J Lavolé Department of Hepato-Gastroenterology, Begin Teaching Military Hospital, Saint-Mandé, France
D Basile Department of Medical Oncology, San Giovanni di Dio Hospital, Crotone, Italy
G Perkins Department of Gastroenterology, CHRU Pontchaillou, Rennes, France
M Jary Department of Surgical and Medical Oncology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
S Stintzing Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Berlin, Germany
J Ros Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
D Tougeron Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France
J Taieb Department of Gastroenterology and Digestive Oncology, Paris-Cité University, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France.

Collapse

Tang J, Peng W, Tian C, Zhang Y, Ji D, Wang L, Jin K, Wang F, Shao Y, Wang X, Sun Y. Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study. Int J Surg 2024;110:4559-4570. [PMID: 38742845 PMCID: PMC11326018 DOI: 10.1097/js9.0000000000001584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 04/25/2024] [Indexed: 05/16/2024]

Abstract

BACKGROUND

Early-onset colorectal cancer (EOCRC) is associated with a poorer prognosis relative to late-onset colorectal cancer (LOCRC), and its incidence has witnessed a gradual escalation in recent years. This necessitates a comprehensive examination of the underlying pathogenesis and the identification of therapeutic targets specific to EOCRC patients. The present study aimed to delineate the distinct molecular landscape of EOCRC by juxtaposing it with that of LOCRC.

METHODS

A total of 11 344 colorectal cancer patients, diagnosed between 2003 and 2022, were enrolled in this study, comprising 578 EOCRC cases and 10 766 LOCRC cases. Next-generation sequencing technology was employed to assess the tumor-related mutation and tumor mutation burden (TMB) in these patients. PD-L1 expression was quantified using immunohistochemistry. Microsatellite instability (MSI) was determined via capillary electrophoresis (2B3D NCI Panel).

RESULTS

Upon comparing LOCRC with EOCRC patients, the latter group demonstrated a tendency towards advanced TNM stage, lower tumor differentiation, and less favorable histological types. Among LOCRC patients, those with MSI-H status were found to have an earlier TNM stage compared to those with MSI-L/MSS status. Significantly, the incidence of MSI-H was notably higher in EOCRC (10.2%) compared to LOCRC (2.2%). Mutations in the 7-gene panel (ARID1A, FANCI, CASP8, DGFRA, DPYD, TSHR, and PRKCI) were more prevalent in LOCRC. Within the EOCRC cohort, patients with the MSI-H subtype displayed an earlier TNM stage but concurrently exhibited poorer tissue differentiation and a higher frequency of mucinous adenocarcinoma. Among EOCRC patients, FBXW7, FAT1, ATM, ARID1A, and KMT2B mutations were significantly enriched in the MSI-H subgroup. A comparative analysis of MSI-H patients revealed heightened mutation frequencies of FGFBR2, PBRM1, RNF43, LRP1B, FBXW7, ATM, and ARID1A in the EOCRC group. Furthermore, EOCRC patients demonstrated a higher overall TMB, particularly in the MSI-H subtype. PD-L1 expression was elevated in EOCRC and positively associated with MSI status.

CONCLUSIONS

This study revealed a significantly higher MSI-H distribution rate in EOCRC, and EOCRC exhibits a distinct mutational signature coupled with higher PD-L1 expression. These findings hold promise in guiding personalized therapeutic strategies for improved disease management in EOCRC patients.

Collapse

Affiliation(s)

Junwei Tang Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Wen Peng Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Chuanxing Tian Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Yue Zhang Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Dongjian Ji Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Lu Wang Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Kangpeng Jin Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Fufeng Wang Nanjing Geneseeq Technology Inc., School of Public Health, Nanjing Medical University
Yang Shao Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China
Xiaowei Wang Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine
Yueming Sun Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Colorectal Institute of Nanjing Medical University, Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine

Collapse

Gu R, Fang H, Wang R, Dai W, Cai G. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E-mutant colorectal cancer. Clin Transl Med 2024;14:e1764. [PMID: 39073010 PMCID: PMC11283586 DOI: 10.1002/ctm2.1764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 06/23/2024] [Accepted: 07/03/2024] [Indexed: 07/30/2024] Open

Ree AH, Høye E, Esbensen Y, Beitnes ACR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. Oncoimmunology 2024;13:2372886. [PMID: 38952672 PMCID: PMC11216098 DOI: 10.1080/2162402x.2024.2372886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 06/22/2024] [Indexed: 07/03/2024] Open

Affiliation(s)

Anne Hansen Ree Department of Oncology, Akershus University Hospital, Lørenskog, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Eirik Høye Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Tumor Biology, Oslo University Hospital, Oslo, Norway
Ying Esbensen Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway
Ann-Christin R. Beitnes Department of Pathology, Akershus University Hospital, Lørenskog, Norway
Anne Negård Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Radiology, Akershus University Hospital, Lørenskog, Norway
Linn Bernklev Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
Linn Kruse Tetlie Department of Oncology, Sørlandet Hospital, Kristiansand, Norway
Åsmund A. Fretland The Intervention Centre and Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway
Hanne M. Hamre Department of Oncology, Akershus University Hospital, Lørenskog, Norway
Christian Kersten Department of Oncology, Akershus University Hospital, Lørenskog, Norway Department of Research, Sørlandet Hospital, Kristiansand, Norway
Eva Hofsli Department of Oncology, St. Olav’s Hospital, Trondheim, Norway Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Marianne G. Guren Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Oncology, Oslo University Hospital, Oslo, Norway
Halfdan Sorbye Department of Oncology, Haukeland University Hospital, Bergen, Norway Department of Clinical Science, University of Bergen, Bergen, Norway
Hilde L. Nilsen Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway Department of Microbiology, Oslo University Hospital, Oslo, Norway
Kjersti Flatmark Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Tumor Biology, Oslo University Hospital, Oslo, Norway Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway
Sebastian Meltzer Department of Oncology, Akershus University Hospital, Lørenskog, Norway

Collapse

Imai T, Shoji H, Hirano H, Matsuguma K, Awatsu T, Hirose T, Okita N, Takashima A, Kato K. BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab. CNS Oncol 2024;13:2347824. [PMID: 38869444 PMCID: PMC11137764 DOI: 10.1080/20450907.2024.2347824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 04/23/2024] [Indexed: 06/14/2024] Open

González NS, Marchese PV, Baraibar I, Ros J, Salvà F, Rodríguez M, Salvà C, Vaghi C, Alcaraz A, García A, Tabernero J, Élez E. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert Opin Investig Drugs 2024;33:613-625. [PMID: 38775361 DOI: 10.1080/13543784.2024.2349287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Accepted: 04/25/2024] [Indexed: 06/25/2024]

Devalle S, Aran V, Bastos Júnior CDS, Pannain VL, Brackmann P, Gregório ML, Ferreira Manso JE, Moura Neto V. A panorama of colon cancer in the era of liquid biopsy. THE JOURNAL OF LIQUID BIOPSY 2024;4:100148. [PMID: 40027146 PMCID: PMC11863817 DOI: 10.1016/j.jlb.2024.100148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 03/13/2024] [Accepted: 03/13/2024] [Indexed: 03/05/2025]

Germani MM, Vetere G, Santamaria F, Intini R, Ghelardi F, Bensi M, Boccaccino A, Minelli A, Carullo M, Ciracì P, Passardi A, Santucci S, Giampieri R, Persano M, Fenocchio E, Puccini A, Lonardi S, Pietrantonio F, Salvatore L, Cremolini C. Treatment of patients with BRAF^V600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open 2024;9:102996. [PMID: 38613911 PMCID: PMC11024565 DOI: 10.1016/j.esmoop.2024.102996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/13/2024] [Accepted: 03/14/2024] [Indexed: 04/15/2024] Open

Affiliation(s)

M M Germani Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
G Vetere Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
F Santamaria Department of Experimental Medicine, Sapienza University of Rome, Rome
R Intini Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
F Ghelardi Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
M Bensi Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
A Boccaccino Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna
A Minelli Department of Medical Oncology, University Campus Bio-Medico, Rome
M Carullo Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
P Ciracì Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
A Passardi Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola
S Santucci Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna
R Giampieri Oncologia Clinica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Torrette di Ancona, Ancona; Oncologia Clinica, Azienda Ospedaliero-Universitaria delle Marche, Ancona
M Persano Medical Oncology, University Hospital of Cagliari, Cagliari; Medical Oncology, University of Cagliari, Cagliari
E Fenocchio Department of Medical Oncology, University of Turin Medical School, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Turin
A Puccini Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy
S Lonardi Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
F Pietrantonio Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
L Salvatore Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
C Cremolini Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa.

Collapse

Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell Rep Med 2024;5:101435. [PMID: 38417447 PMCID: PMC10982988 DOI: 10.1016/j.xcrm.2024.101435] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 12/01/2023] [Accepted: 01/26/2024] [Indexed: 03/01/2024]

Affiliation(s)

James Larkin Skin and Renal Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London, UK
Richard Marais Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK
Nuria Porta Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
David Gonzalez de Castro Molecular Diagnostics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK
Lisa Parsons University of Edinburgh, Edinburgh, UK; PDD - Thermo Fisher Scientific, Bend, Oregon, USA
Christina Messiou Department of Radiology, The Royal Marsden Hospital NHS Foundation Trust, London, UK
Gordon Stamp Department of Histopathology, The Royal Marsden Hospital NHS Foundation Trust, London, UK
Lisa Thompson Centre for Molecular Pathology, The Royal Marsden Hospital NHS Foundation Trust, London, UK
Kim Edmonds Skin and Renal Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK
Sarah Sarker Skin and Renal Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK
Jane Banerji Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
Paul Lorigan Division of Cancer Sciences, Unviersity of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
Thomas R Jeffry Evans Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
Pippa Corrie Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Ernest Marshall The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
Mark R Middleton Department of Oncology, University of Oxford, Oxford, UK
Paul Nathan Mount Vernon Cancer Centre, East & North Herts NHS Trust, Northwood, UK
Steve Nicholson University Hospitals of Leicester NHS Foundation Trust, Leicester, UK
Christian Ottensmeier University Hospitals Southampton NHS Foundation Trust, Southampton, UK
Ruth Plummer Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
Judith Bliss Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
Sara Valpione Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.
Samra Turajlic Skin and Renal Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.

Collapse

Torresan S, de Scordilli M, Bortolot M, Di Nardo P, Foltran L, Fumagalli A, Guardascione M, Ongaro E, Puglisi F. Liquid biopsy in colorectal cancer: Onward and upward. Crit Rev Oncol Hematol 2024;194:104242. [PMID: 38128627 DOI: 10.1016/j.critrevonc.2023.104242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/20/2023] [Accepted: 12/15/2023] [Indexed: 12/23/2023] Open

Ros J, Vivancos A, Tabernero J, Élez E. Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer. Ann Oncol 2024;35:240-241. [PMID: 37866812 DOI: 10.1016/j.annonc.2023.10.120] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 10/11/2023] [Indexed: 10/24/2023] Open

Vogel A, Murugesan K, Kendre G, Quintanilha JCF, Ross JS, Brummer T, Saborowski A. Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer. JCO Precis Oncol 2024;8:e2300411. [PMID: 38394466 DOI: 10.1200/po.23.00411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 10/14/2023] [Accepted: 12/05/2023] [Indexed: 02/25/2024] Open

Saoudi González N, Ros J, Baraibar I, Salvà F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers (Basel) 2024;16:412. [PMID: 38254903 PMCID: PMC10814823 DOI: 10.3390/cancers16020412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 01/10/2024] [Accepted: 01/16/2024] [Indexed: 01/24/2024] Open

Aiman W, Ali MA, Jumean S, Asfeen U, Garcia J, Quirem M, Ahmad A, Rayad MN, Alkhlaifat O, Al Omour B, Chemarthi VS, Maroules M, Guron G, Shaaban H. BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review. J Clin Med 2023;13:113. [PMID: 38202120 PMCID: PMC10779564 DOI: 10.3390/jcm13010113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 12/17/2023] [Accepted: 12/22/2023] [Indexed: 01/12/2024] Open

Affiliation(s)

Wajeeha Aiman Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Muhammad Ashar Ali Department of Internal Medicine, St. Mary’s and St. Clare’s Hospitals, New York Medical College, Denville, NJ 07834, USA
Samer Jumean Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Ummul Asfeen Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Jose Garcia Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Murad Quirem Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Amaar Ahmad Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Mohammad Nabil Rayad Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Osama Alkhlaifat Department of Internal Medicine, Saint Michael’s Medical Center, New York Medical College, Newark, NJ 07102, USA; (W.A.); (S.J.); (U.A.); (J.G.); (M.Q.); (A.A.); (M.N.R.); (O.A.)
Bader Al Omour Department of Hematology/Oncology, Saint Michael’s Cancer Center, New York Medical College, Newark, NJ 07102, USA (V.S.C.); (G.G.); (H.S.)
Venkata S. Chemarthi Department of Hematology/Oncology, Saint Michael’s Cancer Center, New York Medical College, Newark, NJ 07102, USA (V.S.C.); (G.G.); (H.S.)
Michael Maroules Department of Hematology/Oncology, Saint Mary’s Cancer Center, New York Medical College, Passaic, NJ 07055, USA;
Gunwant Guron Department of Hematology/Oncology, Saint Michael’s Cancer Center, New York Medical College, Newark, NJ 07102, USA (V.S.C.); (G.G.); (H.S.)
Hamid Shaaban Department of Hematology/Oncology, Saint Michael’s Cancer Center, New York Medical College, Newark, NJ 07102, USA (V.S.C.); (G.G.); (H.S.)

Collapse

Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano G. Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer 2023;9:1058-1068. [PMID: 37704501 DOI: 10.1016/j.trecan.2023.08.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/17/2023] [Accepted: 08/22/2023] [Indexed: 09/15/2023]

Affiliation(s)

Luca Boscolo Bielo Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Dario Trapani Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Matteo Repetto Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Early Drug Development service, Memorial Sloan-Kettering Cancer Center, New York, USA
Edoardo Crimini Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Carmine Valenza Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Carmen Belli Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
Carmen Criscitiello Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Antonio Marra Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
Vivek Subbiah Drug Development Unit, Sarah Cannon Research Institute, Nashville, TN, USA
Giuseppe Curigliano Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Collapse

Zeng C, Wang M, Xie S, Wang N, Wang Z, Yi D, Kong F, Chen L. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer. J Cancer Res Clin Oncol 2023;149:16111-16121. [PMID: 37639010 DOI: 10.1007/s00432-023-05301-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 08/15/2023] [Indexed: 08/29/2023]

Guerrero P, Albarrán V, San Román M, González-Merino C, García de Quevedo C, Moreno J, Calvo JC, González G, Orejana I, Chamorro J, Martínez-Delfrade Í, Morón B, de Frutos B, Ferreiro MR. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature. Cancers (Basel) 2023;15:5243. [PMID: 37958416 PMCID: PMC10649848 DOI: 10.3390/cancers15215243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 10/25/2023] [Accepted: 10/26/2023] [Indexed: 11/15/2023] Open

Ros J, Baraibar I, Saoudi N, Rodriguez M, Salvà F, Tabernero J, Élez E. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers. Cancers (Basel) 2023;15:4245. [PMID: 37686520 PMCID: PMC10486610 DOI: 10.3390/cancers15174245] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 08/22/2023] [Accepted: 08/23/2023] [Indexed: 09/10/2023] Open

Ros J, Rodríguez-Castells M, Saoudi N, Baraibar I, Salva F, Tabernero J, Élez E. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. Expert Rev Anticancer Ther 2023;23:797-806. [PMID: 37482749 DOI: 10.1080/14737140.2023.2236794] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 07/11/2023] [Indexed: 07/25/2023]